The goal of this clinical trial is to learn how well Altuviiio (efanesoctacog alpha) works for Immune Tolerance Induction (ITI) while using Hemlibra (emicizuma…

Hemophilia A With Inhibitor

~Estimated

~$10 – $7,500

Versiti Blood HealthNCT07158606

Phase 4

Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are e…

Hemophilia A With InhibitorHemophilia B With Inhibitor

~Estimated

~$10 – $7,500

American Thrombosis and Hemostasis NetworkNCT04647227